Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:INSM NASDAQ:LEGN NASDAQ:NKTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.01-0.3%$30.34$16.10▼$41.14$5.26B-0.243.82 million shs8.39 million shsINSMInsmed$105.36-23.1%$145.87$63.81▼$212.75$29.59B0.891.68 million shs13.71 million shsLEGNLegend Biotech$28.57-1.3%$20.20$16.24▼$45.30$5.36B0.292.83 million shs1.36 million shsNKTRNektar Therapeutics$83.37-2.0%$77.37$7.99▼$109.00$2.87B1.241.21 million shs764,261 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+0.37%+0.42%+1.21%+82.27%+115.01%INSMInsmed-1.69%+1.53%-16.31%-9.23%+101.84%LEGNLegend Biotech+1.58%+27.18%+55.03%+73.41%-7.88%NKTRNektar Therapeutics+1.11%+2.27%+13.88%+142.28%+783.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.01-0.3%$30.34$16.10▼$41.14$5.26B-0.243.82 million shs8.39 million shsINSMInsmed$105.36-23.1%$145.87$63.81▼$212.75$29.59B0.891.68 million shs13.71 million shsLEGNLegend Biotech$28.57-1.3%$20.20$16.24▼$45.30$5.36B0.292.83 million shs1.36 million shsNKTRNektar Therapeutics$83.37-2.0%$77.37$7.99▼$109.00$2.87B1.241.21 million shs764,261 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+0.37%+0.42%+1.21%+82.27%+115.01%INSMInsmed-1.69%+1.53%-16.31%-9.23%+101.84%LEGNLegend Biotech+1.58%+27.18%+55.03%+73.41%-7.88%NKTRNektar Therapeutics+1.11%+2.27%+13.88%+142.28%+783.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.04Hold$34.89-14.91% DownsideINSMInsmed 3.00Buy$213.23102.39% UpsideLEGNLegend Biotech 2.67Moderate Buy$58.31104.09% UpsideNKTRNektar Therapeutics 2.73Moderate Buy$140.6368.68% UpsideCurrent Analyst Ratings BreakdownLatest INSM, LEGN, NKTR, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026NKTRNektar Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026INSMInsmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.004/21/2026NKTRNektar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$123.00 ➝ $151.004/21/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$70.00 ➝ $95.004/20/2026NKTRNektar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$151.00 ➝ $178.004/20/2026NKTRNektar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.004/17/2026APLSApellis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.004/17/2026INSMInsmed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$212.004/16/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$230.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$1.00B5.23$0.21 per share196.76$2.93 per share14.00INSMInsmed$606.42M37.50N/AN/A$3.46 per share30.45LEGNLegend Biotech$1.03B5.14N/AN/A$5.43 per share5.26NKTRNektar Therapeutics$55.23M50.93N/AN/A$4.41 per share18.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals$22.39M$0.13315.49N/AN/A2.23%8.20%2.38%5/7/2026 (Estimated)INSMInsmed-$1.28B-$6.41N/A75.80N/A-210.54%-168.36%-57.33%5/7/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.80N/A17.01N/A-28.86%-21.93%-13.21%5/12/2026 (Estimated)NKTRNektar Therapeutics-$164.08M-$10.20N/AN/AN/A-297.07%-380.32%-59.82%5/7/2026 (Estimated)Latest INSM, LEGN, NKTR, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026LEGNLegend Biotech-$0.02N/AN/AN/A$306.51 millionN/A5/7/2026Q1 2026APLSApellis Pharmaceuticals-$0.38$0.15+$0.53$0.15$203.58 million$268.30 million5/7/2026Q1 2026INSMInsmed-$0.9692-$0.76+$0.2092-$0.76$300.81 million$305.96 million5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million3/12/2026Q4 2025NKTRNektar Therapeutics-$2.69-$1.78+$0.91-$1.78$10.44 million$21.81 million3/11/2026Q4 2025LEGNLegend Biotech-$0.17$0.01+$0.18-$0.16$310.21 million$306.30 million2/24/2026Q4 2025APLSApellis Pharmaceuticals-$0.39$0.47+$0.86-$0.45$199.28 million$199.91 million2/19/2026Q4 2025INSMInsmed-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals0.983.142.70INSMInsmed0.763.833.54LEGNLegend BiotechN/A1.961.91NKTRNektar TherapeuticsN/A4.974.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%INSMInsmedN/ALEGNLegend Biotech70.89%NKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%INSMInsmed2.10%LEGNLegend Biotech0.02%NKTRNektar Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770128.02 million119.70 millionOptionableINSMInsmed1,664215.85 million211.32 millionOptionableLEGNLegend Biotech2,965184.96 million184.92 millionOptionableNKTRNektar Therapeutics22033.74 million32.90 millionOptionableINSM, LEGN, NKTR, and APLS HeadlinesRecent News About These CompaniesNektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating3 hours ago | tipranks.comNektar Therapeutics Reports First Quarter 2026 Financial ResultsMay 7 at 4:15 PM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTRMay 7 at 10:00 AM | prnewswire.comNEKTAR DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTRMay 5 at 9:27 PM | newsfilecorp.comNPomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTRMay 5 at 4:29 PM | globenewswire.comDeadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitMay 5 at 1:12 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmMay 5 at 12:00 PM | globenewswire.comNektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still CheapMay 5 at 10:31 AM | seekingalpha.comNKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026May 5 at 9:59 AM | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. InvestorsMay 5 at 9:00 AM | globenewswire.comDeadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMay 5 at 1:04 AM | tmcnet.comNKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud LawsuitMay 4 at 9:54 PM | prnewswire.comNKTR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTRMay 4 at 9:22 PM | newsfilecorp.comNNKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & KorsinskyMay 4 at 8:23 PM | globenewswire.comNEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5thMay 4 at 6:57 PM | globenewswire.comNKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026May 4 at 12:28 PM | newsfilecorp.comNNKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics ...May 4 at 10:01 AM | caledonianrecord.comCNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 4 at 4:41 AM | marketbeat.comNektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMay 4 at 4:02 AM | prnewswire.comNKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law FirmMay 4 at 4:01 AM | prnewswire.comNKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTRMay 3, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSM, LEGN, NKTR, and APLS Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$41.01 -0.11 (-0.27%) Closing price 04:00 PM EasternExtended Trading$41.00 -0.01 (-0.02%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Insmed NASDAQ:INSM$105.36 -31.73 (-23.15%) Closing price 03:59 PM EasternExtended Trading$107.80 +2.44 (+2.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Legend Biotech NASDAQ:LEGN$28.57 -0.39 (-1.35%) Closing price 04:00 PM EasternExtended Trading$28.81 +0.24 (+0.84%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Nektar Therapeutics NASDAQ:NKTR$83.37 -1.72 (-2.02%) Closing price 04:00 PM EasternExtended Trading$83.57 +0.20 (+0.24%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
